Clinical and laboratory study on the effects of green tea on the treatment of patients with Smear positive TB

Comparing Green Tea and Placebo on Blood iron indices, Sputum Smear Conversion and Expression of Hepcidin and Transferrin receptor Genes in Smear Positive TB Patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201212232602N11

Enrollment

Registered

2013-04-07

Start date

2013-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Tuberculosis. Tuberculosis of lung, confirmed by sputum microscopy with or without culture

Interventions

Intervention 1: The control group will receive placebo capsules for two months daily beside the anti-tuberculosis therapy. Intervention 2: The intervention group will receive green tea capsules 400 mg

The control group will receive placebo capsules for two months daily beside the anti-tuberculosis therapy.

The intervention group will receive green tea capsules 400 mg daily beside the anti-tuberculosis therapy.

Eligibility

Sex/Gender

All

Age

16 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Definitive diagnosis of TB according to Ministry of Health criteria; Location in Golestan Province ; treatment of patients under DOTS strategy; Age 15 years and over; Willingness to cooperate in study Exclusion criteria : Allergic symptoms or side effects of green tea consumption; Severe changes in liver function tests due to anti-TB drugs; Side-effects of anti-TB drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sputum smear conversion. Timepoint: from day 20 to 60 every 10 days. Method of measurement: microscopic smear of sputum.	—

Secondary

Measure	Time frame
Hemoglobin. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.;Transferrin receptor gene expression. Timepoint: begining of treatment and end of second month. Method of measurement: real time PCR.;Hepcidin gene expression. Timepoint: begining of treatment and end of second month. Method of measurement: real time PCR.;TIBC. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.;Transferrin. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.;Ferritin. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.	—

Measure

Time frame

Hemoglobin. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.;Transferrin receptor gene expression. Timepoint: begining of treatment and end of second month. Method of measurement: real time PCR.;Hepcidin gene expression. Timepoint: begining of treatment and end of second month. Method of measurement: real time PCR.;TIBC. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.;Transferrin. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.;Ferritin. Timepoint: begining of treatment and end of second month. Method of measurement: laboratory measurement.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Honarvar

Golestan University of Medical Sciences

honarvar@goums.ac.ir+98 17 1442 0199

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026